Competition Markets Authority
Phase 2
Administrative timetable
Referral date: 20 December 2022
Statutory deadline: 5 June 2023
- (20.1.23)
Contact
Provisional findings
20 April 2023: The CMA has provisionally found competition concerns as part of its in-depth investigation of the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical. The full text shall be published later.
The deadline for submitting responses to the provisional findings is Thursday 11 May 2023.
The deadline for submitting responses to the notice of possible remedies is Thursday 4 May 2023.
-
(20.4.23)
-
(20.4.23)
-
(20.4.23)
-
Press Notice: Hearing implants deal could mean worse outcomes for patients (20.4.23)
Responses to the issues statement
- (21.3.23)
- (20.3.23)
Issues statement
20 January 2023: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions. The deadline for submissions on the issues statement is 5pm, 3 February 2023.
- (20.1.23)
Inquiry group appointed
21 December 2022: The CMA has appointed the inquiry group.
Kip Meek (Chair), Anne Fletcher, Keith Richards and David Thomas.
Terms of reference
20 December 2022: The CMA has referred the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical, for an in-depth investigation.
- (20.12.22)
Statutory timetable
Phase 1 | Action |
---|---|
6 December 2022 | Phase 1 decision announced |
14 November 2022 | Initial enforcement order |
11 October 2022 to 25 October 2022 | Invitation to comment |
11 October 2022 | Launch of merger inquiry |
Phase 1
Reference decision
20 December 2022: The CMA has referred the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical, for an in-depth investigation, on the basis that, on the information currently available to it, it is or may be the case that this merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom.
- (20.12.22)
Reference unless undertakings accepted
6 December 2022: The CMA has decided, on the information currently available to it, that it is or may be the case that this merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom. This merger will be referred for a phase 2 investigation unless the parties offer acceptable undertakings to address these competition concerns.
- (20.1.23)
- (6.12.22)
- Press release: Hearing implants merger could mean worse deal for NHS and patients (6.12.22)
Initial enforcement order
14 November 2022: The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Demant A/S and its Oticon Medical subsidiaries, in relation to the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical.
- (17.11.22)
Amendments/consents granted:
- (27.3.23)
- (3.3.23)
- (24.2.23)
- (24.2.23)
- (8.2.23)